T1	Participants 54 103	patients with advanced non-small-cell lung cancer
T2	Participants 805 969	Patients received CDDP 75 mg/m(2) plus DCT 75 mg/m(2) on day 1 every weeks (arm A) or CDDP 80 mg/m(2) on day 1 plus VNR 30 mg/m(2) day 1 and 8 every 3 weeks (arm B)
T3	Participants 2732 2806	treatment decision-making for pts with advanced non-small-cell lung cancer
